Real-time Estimate
Cboe BZX
03:13:31 2024-06-12 pm EDT
|
5-day change
|
1st Jan Change
|
8.67
USD
|
-3.67%
|
|
+56.83%
|
+3.44%
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Capitalization
1 |
365.4
|
1,419
|
801.6
|
1,001
|
501.5
|
552.7
|
-
|
-
|
Enterprise Value (EV)
1 |
365.4
|
942.2
|
405.9
|
1,001
|
501.5
|
461.7
|
461.7
|
552.7
|
P/E ratio
|
-6.47
x
|
-17.4
x
|
-7.51
x
|
-5.91
x
|
-2.52
x
|
-2.71
x
|
-3.16
x
|
-5.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
104
x
|
38.2
x
|
4.68
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
86.8
x
|
31.9
x
|
4.68
x
|
EV / EBITDA
|
-
|
-
|
-3.49
x
|
-5.73
x
|
-
|
-2.01
x
|
-
|
-
|
EV / FCF
|
-5.45
x
|
-14.8
x
|
-4.8
x
|
-7.68
x
|
-
|
-1.98
x
|
-2.23
x
|
-5.21
x
|
FCF Yield
|
-18.4%
|
-6.77%
|
-20.8%
|
-13%
|
-
|
-50.6%
|
-44.8%
|
-19.2%
|
Price to Book
|
1.99
x
|
2.85
x
|
1.95
x
|
1.8
x
|
-
|
2.11
x
|
-
|
-
|
Nbr of stocks (in thousands)
|
36,646
|
46,493
|
47,206
|
56,655
|
61,388
|
61,415
|
-
|
-
|
Reference price
2 |
9.970
|
30.51
|
16.98
|
17.66
|
8.170
|
9.000
|
9.000
|
9.000
|
Announcement Date
|
6/3/20
|
5/20/21
|
5/19/22
|
5/18/23
|
5/16/24
|
-
|
-
|
-
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
5.319
|
14.47
|
118.1
|
EBITDA
1 |
-
|
-
|
-116.2
|
-174.6
|
-
|
-229.2
|
-
|
-
|
EBIT
1 |
-56.2
|
-79.96
|
-118.3
|
-177.1
|
-234.8
|
-244.1
|
-242.8
|
-147.1
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-4,588.84%
|
-1,677.84%
|
-124.5%
|
Earnings before Tax (EBT)
1 |
-52.62
|
-80.87
|
-118
|
-174
|
-215.4
|
-238
|
-240.4
|
-144.9
|
Net income
1 |
-52.62
|
-80.87
|
-118
|
-174.3
|
-215.8
|
-233.5
|
-240.4
|
-144.9
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-4,390.92%
|
-1,661.62%
|
-122.68%
|
EPS
2 |
-1.540
|
-1.750
|
-2.260
|
-2.990
|
-3.240
|
-3.322
|
-2.850
|
-1.637
|
Free Cash Flow
1 |
-67.09
|
-63.78
|
-84.52
|
-130.3
|
-
|
-233.5
|
-207
|
-106
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-4,390.2%
|
-1,430.48%
|
-89.73%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/3/20
|
5/20/21
|
5/19/22
|
5/18/23
|
5/16/24
|
-
|
-
|
-
|
Fiscal Period: March |
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
2026 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-29.7
|
-31.99
|
-40.88
|
-41.58
|
-41.63
|
-53
|
-55.65
|
-63.83
|
-56.54
|
-58.76
|
-62.27
|
-61.29
|
-62.13
|
-62.99
|
-64.4
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-29.67
|
-31.7
|
-42.25
|
-43.1
|
-39.69
|
-48.95
|
-49.35
|
-60.24
|
-50.65
|
-55.14
|
-59.35
|
-59.45
|
-60.24
|
-61.42
|
-62.19
|
Net income
1 |
-29.67
|
-31.7
|
-42.25
|
-43.1
|
-39.69
|
-49.24
|
-49.56
|
-60.04
|
-51.12
|
-55.08
|
-58.88
|
-58.44
|
-58.55
|
-59
|
-62.19
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.5700
|
-0.6000
|
-0.7800
|
-0.7900
|
-0.6900
|
-0.7400
|
-0.7500
|
-0.9000
|
-0.7700
|
-0.2500
|
-0.8679
|
-0.8584
|
-0.8726
|
-0.8445
|
-0.7500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/3/22
|
5/19/22
|
8/4/22
|
11/3/22
|
2/9/23
|
5/18/23
|
8/3/23
|
11/7/23
|
2/8/24
|
5/16/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
476
|
396
|
-
|
-
|
91
|
91
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-67.1
|
-63.8
|
-84.5
|
-130
|
-
|
-234
|
-207
|
-106
|
ROE (net income / shareholders' equity)
|
-32.7%
|
-23.4%
|
-27.8%
|
-36.1%
|
-
|
-55.9%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-27.1%
|
-20.6%
|
-24.9%
|
-31.5%
|
-
|
-48.3%
|
-
|
-
|
Assets
1 |
194.2
|
393
|
473.2
|
553.9
|
-
|
483.8
|
-
|
-
|
Book Value Per Share
2 |
5.010
|
10.70
|
8.690
|
9.800
|
-
|
4.260
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
6.54
|
2.39
|
2.34
|
2.27
|
-
|
6
|
6
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
112.81%
|
41.46%
|
-
|
Announcement Date
|
6/3/20
|
5/20/21
|
5/19/22
|
5/18/23
|
5/16/24
|
-
|
-
|
-
|
Average target price
14.33
USD Spread / Average Target +59.26% Consensus |
1st Jan change
|
Capi.
|
---|
| +8.72% | 553M | | +48.33% | 56.87B | | +37.15% | 39.72B | | -6.10% | 39.27B | | -6.90% | 28.73B | | +13.48% | 26.21B | | -15.98% | 19.79B | | +32.59% | 12.28B | | +27.98% | 12.23B | | +0.61% | 12.12B |
Other Biotechnology & Medical Research
|